Anti-tumor immunity is driven by self versus non-self discrimination. Many immunotherapeutic approaches to cancer have taken advantage of tumor neoantigens derived from somatic mutations. Here, we demonstrate that gene fusions are a source of immunogenic neoantigens that can mediate responses to immunotherapy. We identified an exceptional responder with metastatic head and neck cancer who experienced a complete response to immune checkpoint inhibitor therapy, despite a low mutational load and minimal pre-treatment immune infiltration in the tumor. Using whole-genome sequencing and RNA sequencing, we identified a novel gene fusion and demonstrated that it produces a neoantigen that can specifically elicit a host cytotoxic T cell response. In a cohort of head and neck tumors with low mutation burden, minimal immune infiltration and prevalent gene fusions, we also identified gene fusion-derived neoantigens that generate cytotoxic T cell responses. Finally, analyzing additional datasets of fusion-positive cancers, including checkpoint-inhibitortreated tumors, we found evidence of immune surveillance resulting in negative selective pressure against gene fusionderived neoantigens. These findings highlight an important class of tumor-specific antigens and have implications for targeting gene fusion events in cancers that would otherwise be less poised for response to immunotherapy, including cancers with low mutational load and minimal immune infiltration.
Anti-tumor immunity is driven by self versus non-self discrimination. Many immunotherapeutic approaches to cancer have taken advantage of tumor neoantigens derived from somatic mutations. Here, we demonstrate that gene fusions are a source of immunogenic neoantigens that can mediate responses to immunotherapy. We identified an exceptional responder with metastatic head and neck cancer who experienced a complete response to immune checkpoint inhibitor therapy, despite a low mutational load and minimal pre-treatment immune infiltration in the tumor. Using whole-genome sequencing and RNA sequencing, we identified a novel gene fusion and demonstrated that it produces a neoantigen that can specifically elicit a host cytotoxic T cell response. In a cohort of head and neck tumors with low mutation burden, minimal immune infiltration and prevalent gene fusions, we also identified gene fusion-derived neoantigens that generate cytotoxic T cell responses. Finally, analyzing additional datasets of fusion-positive cancers, including checkpoint-inhibitortreated tumors, we found evidence of immune surveillance resulting in negative selective pressure against gene fusionderived neoantigens. These findings highlight an important class of tumor-specific antigens and have implications for targeting gene fusion events in cancers that would otherwise be less poised for response to immunotherapy, including cancers with low mutational load and minimal immune infiltration.
The mammalian immune system has the ability to reject cancer cells through recognition of immunostimulatory neoantigens and T cell-mediated cytotoxicity 1, 2 . This mechanism is the basis for major recent breakthroughs in cancer immunotherapies, including immune checkpoint inhibitors 3 and adoptive T cell therapy 4 . In addition, personalized RNA or peptide vaccines have been shown to prime host immunity against tumor cells 5 . However, most patients do not experience clinical benefit from these therapies. Improved identification of tumor neoantigens that elicit T cell responses will be needed to increase the scope of benefit from cancer immunotherapy.
Response to immune checkpoint blockade is correlated with high tumor somatic mutational burden (TMB) and high clonality of mutation-associated neoantigens [6] [7] [8] . A low mutational load does not preclude response to immunotherapy, and some responses have been attributed to cancer germline antigens and viral antigens [9] [10] [11] . Several cancer types with low TMB are characterized by clonal oncogenic drivers that are products of gene fusions. Fusion peptides may generate effective tumor-regression antigens, anticipated to be more immunologically foreign than missense mutations. However, it is currently unknown whether fusion proteins can mediate responses to immunotherapy, especially as fusion-positive cancers have a lower TMB 12 . Patient MSK-HN1, an exceptional responder to immunotherapy, presented with a head and neck squamous cell carcinoma (HNSCC) arising at the skull base, with lung metastases. The primary tumor was not surgically resectable. After the discovery of distant metastases, the patient was treated with platinum and 5-fluorouracil chemotherapy, initially resulting in stable disease for 1 year, but followed by disease progression (Fig. 1a) . Six months after the last chemotherapy treatment, the patient began treatment with an anti-PD-1 antibody (pembrolizumab), which induced a radiographic response after 5 months and complete regression of disease by 8 months (Fig. 1b) . The patient was treated for an additional year, completed treatment at 20 months and remains disease free at 30 months.
The histology of the primary tumor before treatment was consistent with squamous cell carcinoma (SCC) (Fig. 1c) and was negative for all (n = 28) human papillomavirus (HPV) serotypes tested by RNA in situ hybridization (see Supplementary Fig. 1 ). The tumor microenvironment demonstrated low immune cell infiltration (see Supplementary Fig. 2 ), most of which were CD3 + CD8 + T cells (Fig. 1d,e) . The primary tumor and a lung metastasis were both negative for PD-L1 staining ( Fig. 1f ; see Supplementary Fig. 2 ). b, Serial imaging of a lung metastasis in the right lower lobe (upper panels, computed tomography (CT) scans: yellow arrows) and a metastasis in the left lower lobe (lower panels, fused positron emission tomography (PET)/CT images: yellow arrows). c, H&E staining of the primary tumor. Scans were done at the times indicated. c-f, Immunohistochemistry (IHC) staining of the same tissue section for H&E (c), CD3 (d), CD8 (e) and PD-L1 (f). IHC staining was performed twice. g, Circos plot of genomic alterations in the tumor identified with WGS. Blue lines indicate SNVs, and the red arc indicates the translocation fusing DEK and AFF2. h, Diagram of the in-frame DEK-AFF2 fusion with nucleotide (nt) and amino acid (aa) sequences surrounding the junction shown. i, FISH detection of the DEK-AFF2 fusion, performed in triplicate. Arrows indicate co-localization of DEK (red) and AFF2 (green). j, Plot of mean Z-scores across the Cancer Genome Atlas (TCGA) HNSCC samples (n = 521) and patient MSK-HN1 tumor, representing the composite of eight immune metrics (see Methods).
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Whole-genome sequencing (WGS) of DNA from a frozen sample of the primary tumor (obtained before immunotherapy) revealed a low non-synonymous mutation rate (0.47 mutations per megabase; 14 single nucleotide variations (SNVs) in 12 genes) and a novel inframe DEK-AFF2 gene fusion ( Fig. 1g,h ; see Supplementary Table 1) .
DEK has been previously demonstrated to have oncogenic properties in HNSCC and other cancer types 13 , and the DEK-NUP214 fusion (in acute myeloid leukemia) is sufficient to transform hematopoietic progenitor cells 14 . The DEK-AFF2 fusion was the likely driver event in this tumor, because none of the mutated genes are included in the COSMIC Cancer Gene Census, or are highly recurrent in sequenced tumors 15 (see Supplementary Table 1 ). There were also no areas of significant copy number alteration or structural variants across the genome (see Supplementary Fig. 3 ). We confirmed the presence of the DEK-AFF2 fusion with RNA sequencing (RNA-seq) (see Extended Data Fig. 1 ) and by fluorescence in situ hybridization (FISH) in tumor tissue (Fig. 1i) . We confirmed a lack of viral (HPV or other) DNA by examining unmapped and partially mapped reads from WGS using GEM Mapper.
To place the immune microenvironment of this tumor in context, we analyzed RNA-seq data from this tumor and 521 other HNSCC tumors in the TCGA dataset to deconvolve infiltrating immune cells and measure markers of T cell activation ( Fig. 1j ; see Supplementary Fig. 4 ) 16 . Consistent with the IHC data, the MSK-HN1 tumor ranked toward the lower end (12th percentile) of the range of immune infiltration scores observed in HNSCCs.
To dissect potential mechanisms underlying the beneficial clinical response to anti-PD-1 treatment, we investigated whether neoantigens derived from SNVs or the DEK-AFF2 fusion could elicit immunostimulatory T cell responses (Fig. 2a) . We used NetMHCpan 4.0 to identify SNV-derived (see Supplementary  Table 2) and DEK-AFF2 fusion-derived (see Supplementary  Table 3 ) peptides that are nine amino acids long and predicted to bind to patient-specific human leukocyte antigens (HLAs) (A*02:01, A*26:01, B*35:01, B*38:01, C*04:01 and C*12:03). As patient MSK-HN1 was positive for HLA-A*02:01, we first tested whether mutation-derived peptides could stabilize the HLA molecule on T2 cells. There was no significant peptide binding to HLA-A*02:01 (see Extended Data Fig. 2a) . However, when HLA-C*04:01 or HLA-C*12:03 was expressed in T2 cells, a DEK-AFF2-derived peptide (DKESEEEVS) stabilized these HLA molecules (P = 0.002, P = 0.003, respectively) (Fig. 2b) . When presented on autologous MSK-HN1 peripheral blood mononuclear cells (PBMCs), DKESEEEVS-stimulated T cell activation, as indicated by interferon-γ (IFN-γ) secretion (P = 1.63 × 10 −16 ) (Fig. 2c,d ) and CD137-positive staining of CD8 + T cells (P = 0.0002) ( Fig. 2e and see Extended Data Fig. 3a) . Moreover, DKESEEEVS-stimulated T cell activation was abrogated when PBMCs were treated with anti-major histocompatibility complex class I (MHC-I) antibody (see Extended Data Fig. 3b ), indicating that DKESEEEVS neoantigen presentation is MHC-I dependent. None of the other tested SNV-or fusion-derived peptides elicited these responses ( Fig. 2d ; see Extended Data Fig. 2b) .
For further confirmation of these results, we cloned the region of DEK that is N-terminal to the fusion breakpoint (DEK-N-term), or DEK fused to an equal length of AFF2 C-terminal to the breakpoint (DEK-AFF2) into pLVX-puro (see Supplementary Table 4) , and transduced SCC-9 cells, which are HLA-C*04:01-positive 17 ( Fig. 2f) . Expression of DEK-AFF2 induced a cytotoxic T cell response against SCC-9 cells, as measured by IFN-γ ELISpot assay (P = 0.0006) which was inhibited when SCC-9 cells were treated with anti-MHC-I antibody ( Fig. 2g,h ; see Extended Data Fig. 3c) . A similar response was observed for COS-7 cells co-transfected with HLA-C*04:01 and pLVX-DEK-N-term or pLVX-DEK-AFF2 (P = 0.0301) (see Extended Data Fig. 3d ). DEK-AFF2 expression increased target cell apoptosis, as indicated by active caspase-3 staining (P = 0.0064, 0.0092 for T cell/target cell ratio of 2:1 and 4:1, respectively) (Fig. 2i ). In addition, effector memory T cells induced further target cell apoptosis (see Extended Data Fig. 3e ), indicating that experienced neoantigen-reactive T cells were present in this patient's blood. Taken together, these data indicate that the immunodominant epitope underlying regression of the patient's metastatic tumors was most probably derived from the DEK-AFF2 fusion, rather than a missense mutation.
We then asked whether there was evidence for a DEK-AFF2-specific T cell response in this patient during response to immunotherapy. We first profiled the T-cell clones associated with the DEK-AFF2 fusion, by sequencing the T cell receptor (TCR) β chain's complementarity-determining region 3 (CDR3) in DKESEEEVS-reactive T cells, compared with an unselected T cell population. In addition we performed TCR sequencing in DNA obtained from the patient's pre-treatment tumor biopsy and on-treatment PBMCs. The CDR3s in the patient's blood were significantly enriched for DKESEEEVSreactive T cell CDR3s, compared with bulk CDR3s (P = 0.016). The most prevalent T cell clone identified in both DKESEEEVSreactive T cells and patient blood (SSPRGNEQF, comprising 28% of ). e, Flow cytometry analysis of CD137 expression of MSK-HN1 T cells after co-culture with autologous PBMCs (n = 3) pulsed with 10 µM AFF2-DEK-derived or DEK-AFF2-derived peptides (ANOVA followed by Dunnett's correction for multiple comparisons; 95% CI = −4.804 to −1.556, ) were not identified in the pre-treatment tumor, but were detected in the blood at the first on-therapy timepoint (5 months), declined in the blood as the tumor responded, but remained detectable at 21 months on-therapy ( Fig. 2j ; see Supplementary Table 5 ). These data are consistent with a DEK-AFF2 neoantigen-specific, T cell response occurring during tumor regression. As has been described previously, tumor-reactive T cells are often undetectable in the intratumoral TCR repertoire 18 , but can become apparent during immunotherapy-mediated tumor regression 8 . We cannot rule out other unexamined sources of neoantigens, such as cancer germline antigens aberrantly expressed due to epigenetic alterations. However, in this tumor, none of the 27 well-described cancer germline antigens were highly expressed, making it less likely (see Supplementary Table 6 ). There were no other structural variants identified on WGS. We identified and tested neoepitopes resulting from possible alternative splicing events (see Supplementary  Table 7) , none of which elicited a T cell response in patient PBMCs (see Extended Data Fig. 2c ). Therefore, in this tumor, other than the fusion neoantigen, we could not find evidence for any other tumor regression antigens such as mutation, viral, germline or alternative splicing-associated antigens.
We then sought to determine whether fusion-associated neoantigens might be able to stimulate T cell responses in similar cancers with a low TMB and minimally immune-infiltrated microenvironments. Adenoid cystic carcinomas (ACCs) are a type of head and (Fig. 3a) , lower immune infiltration than other major cancer types ( Fig. 3b ) and prevalent MYB-NFIB gene fusions, which occur in approximately 60% of cases 19 . We performed RNA-seq of 20 frozen head and neck ACC tumors and utilized INTEGRATE-Neo to call gene fusion transcripts and predict HLAbinding affinity (NetMHC 4.0) (Fig. 3c ). There were 13 patients with tumors with MYB-NFIB or MYBL1-NFIB fusion genes, of whom 7 had the HLA-A2 genotype. We tested the ability of predicted HLA-A2 family-binding peptides (see Supplementary Table 8) to stabilize HLA-A*02:01 on the surface of T2 cells (see Extended Data Fig. 4 ). We found that three MYB-NFIB-derived peptides (SLASPLQSWYL, SLASPLQPT and QFIDSSWYL) and one NFIB-MYB-derived peptide (MMYSPICLTQT) could bind HLA-A*02:01. We first focused on the nonamer QFIDSSWYL from the tumor of a patient from whom we could obtain fresh blood samples.
Patient ACC_M9 presented with a head and neck ACC tumor (see Supplementary Fig. 5 ) and multiple lung metastases, and has not been treated with immunotherapy. RNA-seq identified three MYB-NFIB fusions and the reciprocal NFIB-MYB fusion (see Extended Data Figs. 5 and 6). Whole-exome sequencing (WES) of peripheral blood confirmed the HLA-A*02:01 genotype (Optitype). We cloned the three MYB-NFIB fusions found in the patient's tumor ( Fig. 3d ; see Supplementary Table 9 ) and expressed them in HLA-A*02:01-positive dendritic cells. MYB-NFIB fusion 2, which encompasses the QFDISSWYL peptide, induced IFN-γ secretion by patient T cells (P = 0.002) ( + and CD8 + cells (Fig. 3f,g ). Furthermore, T2 cells pulsed with QFIDSSWYL peptide, but not the related octamer (FIDSSWYL) or decamer (LQFIDSSWYL) peptides, stimulated a significant T cell response (P = 0.037) ( To determine whether peptide-specific T cells can be selectively expanded, patient T cells were co-cultured with peptide-pulsed T2 cells or peptide-pulsed patient PBMCs for 21 d. In both cases, staining with QFIDSSWYL-dextramer-PE demonstrated peptidespecific CD8 + T cell expansion ( We tested whether fusion transcripts encompassing MMYSPICLTQT and SLASPLQPT are translated and processed in cells by cloning the fusions into pcRNA6SL (see Extended Data Fig.  6 and Supplementary Fig. 6 ). These constructs were expressed in autologous dendritic cells, which stimulated corresponding peptidespecific HD2 T cells, whereas dendritic cells expressing MYB-Nterm did not ( Fig + T cells demonstrated induced CD137 expression (Fig. 4d ). These data indicate that neoantigen-specific T cell responses to cancer-associated fusion peptides can be induced in the T cell repertoire of healthy donors, similar to findings for mutation-derived neoantigens in melanoma. This implies that fusion-derived neoantigens may engender T cell responses from independent sources, even if the patient's autologous T cells do not demonstrate detectable reactivity 20 .
To understand the broader implications of fusion peptide antigenicity, we analyzed RNA-seq data to describe the immune microenvironment in 30 TCGA cancer types with gene fusions, and determine whether there was an association between measures of immune surveillance and the presence of a fusion neoantigen. Of 5,825 fusion-positive cancer samples, 1,404 (24%) tumors had a gene fusion neoantigen predicted to bind to patient-specific HLA 12 .
In multivariable logistic regression analysis controlling for TMB, cancer histology and tumor purity, tumors with higher leukocyte fraction (P = 0.004), higher lymphocyte infiltration (P = 0.003) and higher T-helper 1 (T H 1) cell infiltration (P = 0.0002) had a significantly lower likelihood of harboring a fusion neoantigen. For example, for each 10% increase in leukocyte fraction, there was a 7.5% decrease in the odds of observing a fusion neoantigen, adjusting for TMB, cancer type and tumor purity ( Table 10 ). These findings are potentially consistent with a process of immunoediting, leading to negative selection of fusion neoantigens 2 . Another characteristic of tumors linked to immune evasion is somatic loss of heterozygosity (LOH) of the HLA gene locus (LOH-HLA) 21 . We used FACETS to analyze TCGA exome data, identifying LOH-HLA in 18.4% of cases (see Supplementary Table 11 ). LOH-HLA was associated with a higher likelihood of a fusion neoantigen being present (P = 0.018; see Supplementary Table 10 ). Although the determinants of the tumor immune microenvironment are complex and multifactorial, these results reveal a significant inverse association between measures of adaptive immunity and the presence of a fusion neoantigen. Fusion neoantigens were more frequent in tumors with more immunedepleted microenvironments or HLA loss. An important caveat is ). Data are representative of three independent experiments. j, Patient CD8 + T cells that specifically bind to HLA-A*02:01-presented QFIDSSWYL peptide proliferate over 21 d during co-culture with irradiated, peptide-pulsed T2 cells. Peptide-specific T cells were detected with phycoerythrin (PE)-labeled dextramer staining. Fluorescence minus one (FMO) was used to guide the gating strategy. Data are representative of at least two independent experiments. Means ± s.e.m. are plotted, with sample n representing the number of independently treated samples.
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that these analyses are based on in silico predictions of neoantigen binding, and therefore cannot prove that immunoediting is the causal mechanism. Nevertheless, these data are similar to observations that the adaptive immune system can edit, or restrict the emergence of, immunogenic mutations in tumors. Previous studies have shown that somatic mutations and neoantigens are most likely to emerge in the context of low CD3 + /CD8 + T cell infiltration scores, HLA class I gene mutations or poor HLA class I presentation [22] [23] [24] . It will be of interest to determine whether immunotherapies can overcome the often unfavorable immune environment in tumors with fusion neoantigens.
Finally, to assess whether there was evidence of immunoediting of fusion neoantigens during immunotherapy, we analyzed a cohort of tumors with matched pre-and on-treatment biopsies. In these 
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melanomas treated with anti-PD-1 therapy 25 , we analyzed RNAseq data for HLA typing and fusion neoantigen prediction. There were 38 matched pre-and on-therapy (at 4 weeks) pairs with a predicted fusion neoantigen present at one or both timepoints. When comparing all samples pre-to on-therapy, we observed a numerical contraction in the number of fusion neoantigens (mean 2.37 versus 1.76, P = 0.088, Wilcoxon's paired samples test). This difference was most pronounced among tumors experiencing response to therapy (2.22 versus 0.67, P = 0.019), whereas there was no difference in tumors that were stable (2.29 versus 1.71, P = 0.32) or progressing (2.53 versus 2.47, P = 0.94) ( Fig. 4f; see Supplementary Fig. 8 and Supplementary Table 12 ). The contraction observed in responding tumors was limited to fusions predicted to generate neoantigens binding to MHC. In contrast, in responding tumors, there was no contraction of fusions not predicted to generate neoantigens (9.89 versus 9.56, P = 0.67). These data provide supportive evidence of immune-mediated elimination of tumor cells containing fusionderived neoantigens, whereas there was no contraction of non-neoantigen fusions. It is important to note that these tumors harbored many potential neoantigens and that the fusion was not necessarily the immunodominant antigen driving tumor regression.
The advantage of targeting fusions that are putative oncogenic drivers is that they are highly clonal, and it would be disadvantageous for tumors to reduce their expression. The findings presented here have implications for other low mutation burden and/or fusiondriven cancers including EWS-FLI1 in Ewing's sarcoma, EML4-ALK in lung adenocarcinoma, TMPRSS2-ERG in prostate cancer, ETV6-RUNX1, FGFR3-TACC3, TEL-AML1, and others including metastatic cancers and driver fusions 12 . There is some evidence that these findings are likely to gain traction in other cancer types, based on previous in vitro reports of cytotoxic T cell responses against fusion-derived peptides expressed in leukemias (PML-RARα 26 ,
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Methods
Biological samples and whole-genome, whole-exome and RNA sequencing. After obtaining written informed patient consent under an Institutional Review Board-approved tumor biospecimen protocol, tumor samples were obtained from patients undergoing treatment at Memorial Sloan Kettering Cancer Center (MSKCC; protocol no. . Tumors were immediately frozen in liquid nitrogen at the time of surgical resection and stored at −80 °C. Additional tumor was also fixed for paraffin embedding. Blood was drawn from patients MSK-HN1 and ACC_M9 during follow-up visits to the clinic and PBMCs were extracted immediately in the laboratory as described below.
DNA and RNA from patient MSK-HN1 were extracted and underwent WGS and RNA-seq at the New York Genome Center. WGS of patient MSK-HN1 tumor DNA was performed using KAPA Hyper Library Preparation, which involves DNA shearing, repair of fragment ends, A-addition to 3′-ends, ligation to Illumina adapters and PCR amplification with four cycles.
Library preparation of patient MSK-HN1 tumor messenger RNA was performed using the Illumina TruSeq Stranded mRNA Sample Preparation Kit. This involves oligo(dT)-mediated purification of poly(adenylated) mRNA, mRNA fragmentation, cDNA synthesis with Superscript III and random primers (strand specificity maintained by addition of dUTP and RNA-dependent first strand synthesis by addition of actinomycin D), A-tailing, Illumina adapter ligation and PCR amplification with ten cycles. Libraries were subjected to Illumina HiSeq X sequencing, with paired-end 125 base-pair (bp) read lengths.
WGS data from patient MSK-HN1 normal and tumor DNA were aligned to the GRCh37 human reference genome using Burrows-Wheeler Aligner (www. maq.sourceforge.net), duplicate reads marked by NovoSort (www.novocraft.com), and realignment around indels and base calibration with Genome Analysis Toolkit (GATK) (www.broadinstitute.org/gsa/wiki/index.php/The_Genome_Analysis_ Toolkit). Structural variants were determined by NBIC-seq (www.compbio.med. harvard.edu/BIC-seq), Crest (www.stjuderesearch.org/site/lab/zhang), Delly (www. korbel.embl.de/software.html) and BreakDancer (http://breakdancer.sourceforge. net). For patient MSK-HN1 RNA-seq, reads were aligned to the GRCh37.p13 genome using STAR v.2.4.2a. Genes were quantified versus Gencode v.18 (www. gencodegenes.org) annotation using featureCounts from the Subread package (v.1.4.3-p1). FusionCatcher (v.0.99.5a) was used to detect fusions (http://code. google.com/p/fusioncatcher/). The DEK-AFF2 fusion was identified in both WGS and RNA-seq and confirmed by inspection in Integrated Genome Viewer (IGV).
All high-throughput sequencing results were high quality, and all normal and tumor tissue pairs were confirmed as concordant. Normal and tumor DNA from patient MSK-HN1 had 145 million and 282 million reads, respectively, over 99% of which correctly aligned to the reference genome. Mean target coverage for MSK-HN1 was 60× for normal DNA and 90× for tumor DNA, using Picard CollectWgsMetrics. Patient MSK-HN1 tumor RNA-seq yielded over 50 million read pairs (125 bp in length per read), over 97% mapped reads, over 85% gene assignment rate (uniquely mapped reads assigned to exons) and 1.56% rRNA reads. GEM Mapper was used to detect viral sequences from unmapped or partially mapped reads in WGS and RNA-seq (http://gemlibrary.sourceforge.net).
Among the 20 ACC cases, 9 were primary tumors collected at the time of surgery and 11 were biopsies of metastatic sites. All tumor-normal pairs were confirmed as concordant. Two pairs of ACCs were matched primary and metastatic tumors from two individual patients (ACC_P3 and ACC_M3 from one patient, and ACC_P12 and ACC_M12 from another patient). ACC tumor RNA was extracted and subjected to high-throughput RNA sequencing at the MSKCC Integrated Genomics Operation core facility, as described 34 . Normal DNA from peripheral bloods from patients was also subjected to WES at MSKCC. SNVs with an allele read count of less than four or with corresponding normal coverage of less than seven reads were filtered out. Copy number alterations were assessed by FACETS v.0.5.6 (https://sites.google.com/site/mskfacets) with a cval of 300. For alternative splicing event calling, junction coordinates corresponding to non-annotated transcripts were extracted from the STAR alignment results and categorized according to the one of the following alternative splicing events: exon skipping, alternative 5′, alternative 3′, mutually exclusive event. The translational effect (in-frame or out-of-frame) was inferred based on the annotation. A database of novel junctions identified in GTeX and TCGA was used to estimate the prevalence of these junctions. Alternative splicing events absent in GTex or TCGA data, and with high percentage spliced inclusion (ndicating the percentage of transcripts with the event) of 10% or greater were included.
For patient MSK-HN1, all possible neoantigen peptides (nine amino acids long) encompassing the mutated residues (for SNVs), fusion breakpoint (for gene fusions) or alternative splicing events were queried for patient-specific HLA binding by NetMHCpan v.4.0 (http://www.cbs.dtu.dk/services/NetMHCpan). Predicted peptide binding to HLA with <2% Rank is considered significant. All SNV nonamers predicted to bind patient HLA and all fusion peptides regardless of predicted HLA binding were tested for their ability to stimulate patient T cell secretion of IFN-γ.
Neoantigen-HLA-binding predictions for MYB-NFIB, NFIB-MYB and MYBL1-NFIB fusions in ACC samples, and for melanoma samples in the study of Riaz et al. 25 , were generated from the INTEGRATE-Neo algorithm, which identifies transcripts spanning two genes (gene fusion transcripts) from RNA-seq data and queries fusion-derived peptides for HLA binding by using NetMHC v.4.0 (https://github.com/ChrisMaherLab/INTEGRATE-Neo). HLAs were identified from RNA-seq data by the HLAminer algorithm (http://www.bcgsc.ca/platform/ bioinfo/software/hlaminer), which can call more than six HLAs per sample due to sequence similarity among HLA subtypes, and with seq2HLA. Predicted peptide binding to HLA with <500 nM affinity is considered significant. For the samples from Riaz et al. 25 , a total of 43 tumors had complete pre-therapy and on-therapy matched pairs with RNA-seq data available, of which 38 had a fusion neoantigen predicted in at least one sample.
Analysis of immune metrics. TCGA RNA-seq and purity data were downloaded from the NCI GDC Repository (https://portal.gdc.cancer.gov/repository?facetTab =files).
RNA-seq data were aligned to the hg19 genome using STAR aligner, counted using Rsamtools v.1.28 (https://bioconductor.org/packages/release/bioc/html/ Rsamtools.html) and annotated using UCSC hg19.knownGene (http://genome. ucsc.edu). The Union counting mode was used for mapped reads only, and fragments per kilobase of exon per million fragments mapped were obtained with DESeq2 (http://www.bioconductor.org/packages/release/bioc/html/DESeq2.html). Read count capture was performed with Rsamtools and GenomicAlignments package 35 . Several orthogonal tools for the deconvolution of immune infiltration from RNA-seq data were implemented: Immune Infiltration Score and T cell Infiltration Score using single sample gene set enrichment analysis 36 , ESTIMATE Immune Score 37 , Cytolytic Score (CYT) 38 , Cibersort Absolute Score (http:// cibersort.stanford.edu) and Reactome Interferon gamma 39 (http://Reactome.org). The complete TCGA dataset of HNSCCs was analyzed by immune deconvolution methods and ranked along with normalized PD-1 and PD-L1 expression levels to generate a composite Z-score.
For analysis of TCGA cases with gene fusions, fusion data was downloaded from Gao et al. 12 and immune metrics were downloaded from Thorsson et al. 40 . Analysis was limited to 5,825 samples with a fusion gene identified, representing 30 cancer types. We excluded hematologic malignancies (diffuse large B-cell lymphoma, LAML) and non-malignant paragangliomas (pheochromocytoma and paraganglioma). LOH-HLA was determined using FACETS of TCGA WES data with default settings (cbioportal.org). Briefly, segments within the chromosome 6p locus containing the HLA-A, -B and -C loci were identified, and LOH was defined as a minor allele copy number estimate of 0 for any of the HLA loci using the expectation-maximization model 41, 42 . Cancer type and somatic mutational burden were each significantly associated with fusion neoantigen status in univariate analysis, and these were included as co-variates in multivariable analysis. Multivariable logistic regression was used to evaluate the association of the presence of a fusion neoantigen with leukocyte fraction (from methylation data), lymphocyte infiltration (from RNA-seq data), the proportions of infiltrating CD8 + T cells, activated natural killer cells, macrophages, T H 1 cells and T H 2 cells 40 , measures of immune cell activation such as the CYT score 38 and IFN-γ response pathway, and LOH-HLA, in all cases including tumor histology and TMB as co-variates.
Reagents. Peptides were synthesized by Genscript and resuspended in DMSO. Recombinant human β 2 -microglobulin was purchased from BD (catalog no. 551089). Fluorescent peptide-dextramer-PE (QFIDSSWYL-dextramer-PE) complexes were synthesized by Immudex. Cytofix/Cytoperm (BD catalog no. 1-2090KZ) and Perm/wash 10× Buffer (BD catalog no. 51-2091KZ) were used according to the manufacturers' instructions. CellTrace Far Red was purchased from Thermo Scientific (catalog no. C34564). Anti-CD3/CD28 beads were purchased from Gibco (catalog no. 11131D). Recombinant human interleukin (IL)-2 (catalog no. 402-ML-020), recombinant human IL-15 (catalog no. 447-ML-010) and IFN-γ ELISpot plates were purchased from R&D Systems. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF; catalog no. 300-03) and recombinant human IL-4 (catalog no. 200-04) were purchased from Peprotech. All cell media were purchased from Thermo Scientific. Human serum was purchased from Sigma (catalog no. H3667).
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For RNA in situ hybridization of MSK-HN1 tumor samples, probes against high- risk HPV subtypes 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59 , 66, 68, 73 and 82 (HS-HPV HR18), low-risk HPV subtypes 6, 11, 40, 43, 44, 54, 69, 70, 71 and 74 (HPV LR10), probes against HPV E6 and E7 genes and RNAScope 2.5 LS Reagent Kit-Brown were purchased from Advance Cell Diagnostics.
For IHC staining of MSK-HN1 tumor samples, the antibodies are listed with the supplier, catalog number and dilution: anti-CD3 (Leica, catalog no. NCL-L-CD3-565, 1:100), anti-CD8 (Ventana, catalog no. 790-4460, no dilution), anti-CD45 (Ventana, catalog no. 760-2505, no dilution) and anti-PD-L1 (Cell Signaling, catalog no. 13684, 1:800).
For cell-based assays, the antibodies used are listed with the supplier, catalog number and dilution: PE-anti-HLA-A2 clone BB7. Histology and IHC. Histopathologic analyses were conducted by subspecialty pathologists (R. Ghossein and N. Katabi). H&E staining of formalin-fixed paraffinembedded (FFPE) slides was performed by standard histology techniques. IHC staining for CD45, CD3, CD8 and PD-L1 was performed on FFPE slides using standard techniques.
FISH to detect the DEK-AFF2 fusion. FISH analysis was performed at Molecular Cytogenetics Core Facility at MSKCC, on FFPE slides using a probe mix that consisted of BAC clones spanning DEK (6p22; RP11-204B7, RP11-298J15, RP11-95C19; labeled with Red-dUTP) and AFF2 (Xq28; RP11-64L19, RP11-480N18, RP11-1031A22, RP11-75A14; labeled with Green-dUTP). Slides were scanned using a Zeiss Axioplan 2i epifluorescence microscope equipped with a CoolCube 1 CCD camera controlled by Isis v.5.5.10 imaging software (MetaSystems Group Inc.).
Cells. PBMCs were isolated from blood samples by centrifugation in CPT Tubes at 1,500g for 20 min without brakes and extraction of the white cell layer. PBMCs were cultured in complete Iscove's modified Dulbecco's medium (IMDM supplemented with GlutaMax and 10% human serum, 100 U ml -1 penicillin and 100 µg ml -1 streptomycin). Immature dendritic cells were isolated from healthy donor or patient PBMCs using the plastic-adherence method, as described by Tran et al. 43 in AIM-V media supplemented with GM-CSF (1,000 U ml T cells were isolated from PBMCs by pan-expansion using anti-CD3/ anti-CD28 beads, IL-2 (30 U ml -1 ) and IL-15 (10 ng ml -1 ), and cultured in complete IMDM media. Cytokines were replenished every 3 d.
T2 cells, which are TAP deficient, were cultured in IMDM supplemented with 10% fetal bovine serum (FBS), 100 U ml -1 penicillin and 100 µg ml -1 streptomycin. SCC-9 cells were cultured in DME:F12 (1:1) supplemented with 1.2 g l -1 sodium bicarbonate, 2.5 ml l-glutamine, 15 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 0.5 mM sodium pyruvate, 400 ng ml -1 hydrocortisone and 10% FBS.
COS-7 and HEK293 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS.
Fusion construct cloning and expression. RNA extracted from patient MSK-HN1 FFPE slides was used as a template for reverse transcription with oligo(dT) primers. PCR primer sequences and cloning strategies are listed in Supplementary  Table 4 . DEK-N-term (non-neoantigenic control) and DEK-AFF2 fusion were cloned into pcRNA6SL (a kind gift from S. Rosenberg, NIH, Bethesda, MD) and pLVX-Puro (Clontech) via EcoRI and BamHI restriction sites. Similarly, the MYB-N-term and MYB-NFIB and NFIB-MYB fusions were cloned from patient cDNA and inserted into pcRNA6SL by Golden Gate cloning strategies described in Supplementary Table 9 . Plasmid inserts were fully sequenced to confirm proper cloning.
HEK293 cells were transiently transfected with pcRNA-MYB-N-term or pcRNA-MYB-NFIB constructs. Whole-cell lysate was collected after 48 h to confirm the expression of the constructs by immunoblotting with anti-MYB antibody. A full scan of immunoblotting is available at https://figshare.com/ s/8f7da692902f1239ccf0.
Lentiviruses were generated by co-transfection of HEK293 cells with pLVX constructs, psPAX2 and pMD2.G, and used to infect SCC-9 target cells using standard techniques. Infected SCC-9 cells were selected in 1.5 µg ml -1 puromycin. Expression of DEK and DEK-AFF2 was confirmed by immunoblotting with anti-DEK antibody. A full scan of immunoblotting is available at https://figshare. com/s/8eede6b3f4ad46bd6b39. HLA stabilization assays. T2 cells or patient PBMCs, 100,000-500,000, were resuspended in 200 µl complete IMDM with 5 µg ml -1 recombinant human β 2 -microglobulin, and incubated with 10 µM of the indicated peptides for 18 h at 37 °C in 96-well plates (peptide pulse). Cells were stained with fluorescent anti-HLA antibodies for 30 min in the dark at 4 °C.
To IL-4 at 37 °C overnight, and were then washed with serum-free RPMI and co-cultured with T cells. Alternatively, T2 cells or PBMCs were pulsed with peptide, as described above, irradiated with 50 Gy and then co-cultured with T cells. T cells, 20,000, were co-cultured with APCs at a 1:1 ratio (unless otherwise stated) in complete IMDM overnight at 37 °C on the IFN-γ ELISpot plates (R&D Systems).
T cells were then extracted from the ELISpot plates, washed with FACS buffer (phosphate-buffered saline with 2% FBS), and stained with fluorophoreconjugated antibodies targeting cell surface proteins (CD4, CD8, PD-1) for 30 min in the dark at 4 °C. Cells were washed three times with FACS buffer and analyzed by flow cytometry. IFN-γ ELISpot plates were developed according to the manufacturer's instructions. Statistical testing was performed using the two-tailed t-test, or the single-tailed t-test if a directional hypothesis was tested in a second orthogonal experiment.
Expansion and detection of fusion neoantigen peptide-specific T cells. PBMCs or T2 cells were pulsed with 10 µM peptides and irradiated with 50 Gy to serve as APCs for T cell expansions. T cells were cultured with the irradiated cells in the presence of IL-2 (30 U ml -1 ) and IL-15 (10 ng ml -1 ) and analyzed on day 21. The cytokines were replenished every 3 d. DKESEEEVS-reactive T cells were detected with IFN-γ secretion assay (Miltenyi Biotec) following the manufacture's protocol. QFIDSSWYL-specific T cells were stained with QFIDSSWYL-dextramer-PE (diluted 1:50 in FACS buffer) for 30 min at room temperature in the dark. Neoantigen-specific T cells were then analyzed/sorted by flow cytometry.
Active caspase-3 assay. SCC-9 cells expressing DEK-N-term or DEK-AFF2 were labeled by CellTrace Far Red and co-cultured with pan-expanded T cells from patient MSK-HN1 for 3 h, and then fixed and permeabilized with Cytofix/ Cytoperm, stained with PE-labeled anti-active-caspase-3 antibody and CellTrace Far Red, and analyzed by flow cytometry.
TCR-Vβ deep sequencing and statistical testing. TCR-Vβ deep sequencing was performed by immune repertoire sequencing (iRepertoire) on mRNA or immunoSEQ (Adaptive Biotechnologies) on genomic DNA isolated from FFPE tumor tissue, PBMCs and T cells. We reasoned that TCRs that are neoantigen specific would be present at an appreciable frequency in the DKESEEEVSstimulated IFN-γ + population and present in at least one of the patient tumor or blood populations. Of the 1525 TCR β-chain CDR3s identified via our IFN-γ capture assay, 121 overlapped with at least one of the patient sample populations. We tested whether the CDR3s identified in patient blood and tissue samples during immunotherapy were enriched for those in the IFN-γ capture assay population, by comparing the overlap of patient sample CDR3s and IFN-γ+ capture T cell CDR3s, compared with unselected (bulk population) CDR3s. Of the 763 clones present above median frequency in the IFN-γ + population, 71 were present in at least one of the blood sample populations. We conducted a permutation test Data analysis GraphPad 7 .04 and SPSS 24 were used to perform the statistical tests indicated in the Methods section.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Whole exome and RNA sequencing data have been deposited in SRA and are available under project number PRJNA527992.
Field-specific reporting 
Authentication
Cell lines were purchased directly from ATCC and cells had the morphology of published or manufacturer-provided images, thus not further authenticated.
Mycoplasma contamination
Cell lines were not tested for mycoplasma.
Commonly misidentified lines (See ICLAC register)
No commonly misidentified cell lines were used.
Human research participants
Policy information about studies involving human research participants
Population characteristics
Patient MSK-HN1 is a female patient. ACC patients had a mean age of 63 years old: 8 male and 10 female. All of these patients provided written informed consent for the collection and analysis of biospecimens under MSKCC IRB approved biospecimen protocol #11-195.
Recruitment
Patient MSK-HN1 was an exceptional responder to anti-PD-1 after progressing on standard of care and was under the clinical care of the senior author. All ACC patient samples collected at MSKCC were included. The ACC patients were also all under the care of the authors.
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation
Cells were resuspended in FACS buffer (PBS + 2% FBS) and incubated with antibodies using standard techniques described in the methods section. 
